Clindamycin Palmitate Hydrochloride Injection shortage
Clindamycin Palmitate Hydrochloride Injection is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Oct 2, 2026.
Amneal Pharmaceuticals is stopping production of clindamycin palmitate hydrochloride injection 75 mg/5 mL, and this change may be permanent. Amneal does list a powder-for-solution form of the same medicine at the same strength, which may be an alternative source.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Clindamycin Palmitate Hydrochloride Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Mar 26, 2026Currently in shortage2 of 2 products affected.
-
Mar 26, 2026More presentations reported1 more product added to the shortage.
-
Feb 27, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Clindamycin Palmitate Hydrochloride Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Clindamycin Palmitate Hydrochloride Injection? options further down this page.
Why is Clindamycin Palmitate Hydrochloride Injection in shortage?
Amneal Pharmaceuticals has reported to the FDA that they are permanently stopping production of their Clindamycin Palmitate Hydrochloride Injection, 75 mg/5 mL. This is a full discontinuation of that specific product from this manufacturer — meaning they do not plan to make it again going forward.
It's worth knowing that the FDA did not share a more specific public reason for why Amneal made this decision — just that the discontinuation of manufacturing is the cause. This report reflects only what Amneal has filed with the FDA, so it speaks only to their version of this product.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Clindamycin Palmitate Hydrochloride Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Clindamycin Palmitate Hydrochloride Injection?
Clindamycin Palmitate Hydrochloride Injection is currently on the FDA drug-shortage list. I want to walk you through what this means so you can plan your next step calmly.
The only strength on this record — 75 mg/5 mL — has no available source reported at this time. The manufacturer that filed this report, Amneal Pharmaceuticals, has listed this product as being discontinued, which means this particular supply problem may be permanent rather than temporary. Because this is a national, manufacturer-reported report, it does not reflect every maker or what your local pharmacy actually has on its shelves.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — keep taking it as prescribed while you sort out supply.
- Ask your pharmacy to check with wholesalers and other manufacturers; they can often locate stock that is not visible from a national list.
- The same medicine in the same 75 mg/5 mL strength is also listed as a powder for solution from Amneal Pharmaceuticals LLC — your pharmacy may be able to source it, though it may not be in local stock.
- Because this product is being discontinued, please talk with your prescriber or pharmacist about a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Clindamycin Palmitate Hydrochloride Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Clindamycin Palmitate Hydrochloride Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Clindamycin Palmitate Hydrochloride (Pediatric) | CLINDAMYCIN PALMITATE HYDROCHLORIDE 75 mg/5mL | Powder, For Solution · Oral | Amneal Pharmaceuticals LLC | 65162-0468-19 |
Alternative dosage forms of Clindamycin Palmitate Hydrochloride
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 10 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Clindamycin Palmitate Hydrochloride (Pediatric) 75 mg/5mL | NorthStar | 1 bottle | $0.129 | AA | Availability likely |
| clindamycin palmitate hydrochloride 75 mg/5mL | Heritage | 1 bottle | $0.129 | AA | Availability likely |
| Clindamycin Palmitate Hydrochloride (Pediatric) 75 mg/5mL | Amneal | 1 bottle | $0.129 | — | Availability likely |
| CLINDAMYCIN PALMITATE HYDROCHLORIDE (Pediatric) 75 mg/5mL | Rising | 100 ml | $0.129 | AA | Availability likely |
| Clindamycin Palmitate Hydrochloride (Pediatric) 75 mg/5mL | Amneal | 1 bottle | $0.129 | — | Discontinued |
| Clindamycin Palmitate Hydrochloride (Pediatric) 75 mg/5mL | Aurobindo | 1 bottle | $0.129 | AA | Availability likely |
| Cleocin Pediatric 75 mg/5mL | Pharmacia | 1 bottle | — | AA | Discontinued |
| Clindamycin Palmitate Hydrochloride 75 mg/5mL | Chartwell | 100 ml | — | AA | FDA listed |
| CLINDAMYCIN PALMITATE HYDROCHLORIDE (Pediatric) 75 mg/5mL | Bryant | 100 ml | — | AA | FDA listed |
| CLINDAMYCIN PALMITATE HYDROCHLORIDE (Pediatric) 75 mg/5mL | Bryant | 100 ml | — | AA | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Clindamycin Palmitate Hydrochloride Injection — that fall in the same broad treatment class (lincosamide antibiotics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other anti-infective shortages
Clindamycin Palmitate Hydrochloride Injection shortage FAQs
Is Clindamycin Palmitate Hydrochloride Injection in shortage?
Which products are affected?
When will Clindamycin Palmitate Hydrochloride Injection be available again?
Can I still get Clindamycin Palmitate Hydrochloride somewhere?
What should I do if I take Clindamycin Palmitate Hydrochloride Injection?
Still have a question about the Clindamycin Palmitate Hydrochloride Injection shortage?
Ask a pharmacist about this shortage →View Clindamycin Palmitate Hydrochloride Inje... on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.